The CAPRISA 004 trial assessed effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the prevention of HIV acquisition in women. A double-blind, randomized controlled trial was conducted comparing tenofovir gel with placebo gel in sexually active, HIVuninfected18 to 40 year-old women in urban and rural KwaZulu-Natal, South Africa HIV serostatus, safety,sexual behavior and gel and condom use were assessed at monthly follow-up visits for 30 months.
Follow us @PLRI
Court-based research: collaborating with the justice system to enhance STI services for vulnerable women in the US http://t.co/3vEaFQVO
The fractal queerness of non-heteronormative migrant #sexworkers in the UK by Nick Mae http://t.co/X7oGFeDI
‘only 31% of the sample of indirect sex workers reported having been engaged in commercial sex in the last 12 months’
Old but good. Violence and Exposure to HIV among #sexworkers in Phnom Penh http://t.co/rkrRGiBa
Someone is Wrong on the Internet: #sex workers’ access to accurate information
PLRI WEBSITE NEWS – 2014